Alterations in plasma lecithin: Cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: Implications for cardiac outcome

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages

  Dullaart, Robin P F ^a   Tietge, Uwe J F ^a   Kwakernaak, Arjan J ^a   Dikkeschei, Bert D ^b   Perton, Frank ^a   Tio, René A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

Author keywords

Acute coronary syndrome; Atypical chest pain; Lecithin:cholesterol acyltransferase; Myeloperoxidase; Non STEMI; STEMI

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTIVITAMIN K; APOLIPOPROTEIN A; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CREATINE KINASE; CREATINE KINASE MB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; TROPONIN T; PEROXIDASE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMILUMINESCENCE IMMUNOASSAY; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONCARDIAC CHEST PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; AGED; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; HEART INFARCTION; INCIDENCE; MIDDLE AGED;

AGED; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEROXIDASE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 84897988375     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.02.026     Document Type: Article

References (45)

1. Linsel-Nitschke P., Tall A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005, 4:193-205.
2. Lewington S., Whitlock G., Clarke R., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839. Prospective Studies Collaboration.
3. Glomset J.A. The plasma lecithin:cholesterol acyltransferase reaction. JLipid Res 1968, 9:155-162.
4. de Vries R., Borggreve S.E., Dullaart R.P.F. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab 2003, 49:601-613.
5. Calabresi L., Simonelli S., Gomaraschi M., Franceschini G. Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis 2012, 222:299-306.
6. Rousset X., Shamburek R., Vaisman B., Amar M., Remaley A.T. Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?. Curr Atheroscler Rep 2011, 13:249-256.
7. Tanigawa H., Billheimer J.T., Tohyama J., et al. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport invivo. Circulation 2009, 120:160-169.
8. Dullaart R.P.F., Perton F., Sluiter W.J., de Vries R., van Tol A. Plasma lecithin:cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. JClin Endocrinol Metab 2008, 93:4860-4866.
9. Calabresi L., Baldassarre D., Simonelli S., et al. Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk. JLipid Res 2011, 52:1569-1574.
10. Dullaart R.P.F., Perton F., van der Klauw M.M., Hillege H.L., Sluiter W.J. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis 2010, 208:537-542. PREVEND Study Group.
11. Holleboom A.G., Kuivenhoven J.A., Vergeer M., et al. Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. JLipid Res 2010, 51:416-421.
12. Wells I.C., Peitzmeier G., Vincent J.K. Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol 1986, 45:303-310.
13. Sethi A.A., Sampson M., Warnick R., et al. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem 2010, 56:1128-1137.
14. Solajić-Bozicević N., Stavljenić A., Sesto M. Lecithin:cholesterol acyltransferase activity in patients with acute myocardial infarction and coronary heart disease. Artery 1991, 18:326-340.
15. Patel P.J., Khera A.V., Jafri K., Wilensky R.L., Rader D.J. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. JAm Coll Cardiol 2011, 58:2068-2075.
16. Shao B., Cavigiolio G., Brot N., Oda M.N., Heinecke J.W. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A 2008, 105:12224-12229.
17. Shao B., Oda M.N., Oram J.F., Heinecke J.W. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010, 23:447-454.
18. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. JClin Invest 2004, 114:529-541.
19. McCall M.R., Carr A.C., Forte T.M., Frei B. LDL modified by hypochlorous acid is a potent inhibitor of lecithin-cholesterol acyltransferase activity. Arterioscler Thromb Vasc Biol 2001, 21:1040-1045.
20. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. NEngl J Med 2003, 349:1595-1604.
21. Sawicki M., Sypniewska G., Kozinski M., et al. Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. Eur J Clin Invest 2011, 41:667-671.
22. Apple F.S., Smith S.W., Pearce L.A., et al. Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations. Clin Chem 2011, 57:603-608.
23. Willemsen H.M., de Jong G., Tio R.A., et al. Quick identification of acute chest pain patients study (QICS). BMC Cardiovasc Disord 2009, 9:24.
24. Willemsen H.M., van der Horst I.C., Nieuwland W., et al. The diagnostic value of soluble CD163 in patients presenting with chest pain. Clin Biochem 2009, 42:1662-1666.
25. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand J.P., Hamm C.W., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007, 28:1598-1660.
26. van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: thetask force on the management of ST-segment elevation acute myocardialinfarction of the European Society of Cardiology. Eur Heart J 2008, 29:2909-2945.
27. Diamond G.A., Forrester J.S. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. NEngl J Med 1979, 300:1350-1358.
28. Dutch College of General Practitioners Standaard diabetes mellitus type 2. Huisarts Wet 2006, 3:137-152.
29. Thygesen K., Alpert J.S., Jaffe A.S., et al. Joint ESC/ACCF/AHA/WHF task force forthe universal definition of myocardial infarction. Eur Heart J 2012, 33:2551-2567.
30. Dullaart R.P.F., Sluiter W.J., Dikkeschei L.D., Hoogenberg K., van Tol A. Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 1994, 24:188-194.
31. Florén C.H., Chen C.H., Franzen J., Albers J.J. Lecithin:cholesterol acyltransferase in liver disease. Scand J Clin Lab Invest 1987, 47:613-617.
32. Haase C.L., Tybjærg-Hansen A., Qayyum A.A., et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. JClin Endocrinol Metab 2012, E248-E256.
33. Albers J.J., Chen C.H., Adolphson J.L. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. JLipid Res 1981, 22:1206-1213.
34. Dullaart R.P.F., Constantinides A., Perton F.G., et al. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile. JClin Endocrinol Metab 2011, 96:1077-1084.
35. Dobiasova M., Urbanova Z., Samanek M. Relations between particle size of HDL and LDL lipoproteins and cholesterol esterification rate. Physiol Res 2005, 54:159-165.
36. Huang Y., Wu Z., Riwanto M., et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. JClin Invest 2013, 123:3815-3828.
37. Sugiyama S., Okada Y., Sukhova G.K., et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001, 158:879-891.
38. Meuwese M.C., Stroes E.S., Hazen S.L., et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. JAm Coll Cardiol 2007, 50:159-165.
39. Chen Y., Zhang F., Dong L., Shu X. Long-term prognostic value of myeloperoxidase on acute coronary syndrome: a meta-analysis. Arch Med Res 2011, 42:368-374.
40. Rudolph V., Keller T., Schulz A., et al. Diagnostic and prognostic performance of myeloperoxidase plasma levels compared with sensitive troponins in patients admitted with acute onset chest pain. Circ Cardiovasc Genet 2012, 5:561-568.
41. Riemens S.C., van Tol A., Sluiter W., Dullaart R.P.F. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998, 140:71-79.
42. Corsetti J.P., Gansevoort R.T., Sparks C.E., Dullaart R.P.F. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest 2010, 40:483-489.
43. Dullaart R.P.F., Perton F., Kappelle P.J.W.H., et al. Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of C-reactive protein with HDL cholesterol in non-diabetic men. Biochim Biophys Acta 2010, 1801:84-88.
44. Keller T., Zeller T., Peetz D., et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. NEngl J Med 2009, 361:868-877.
45. Peduzzi P., Concato J., Kemper E., Holford T.R., Feinstein A.R. Asimulation study of the number of events per variable in logistic regression analysis. JClin Epidemiol 1996, 49:1373-1379.